CD8A and neoplasm: The superiority of YD over Y45 and IL‐2 in promoting tumor regression was diminished when mice were co‐administered with a CD8‐depleting antibody or FTY720 (Figure S8d‐f, Supporting information), an inhibitor of lymphocyte egress from lymph nodes.[49] This underscores the critical role of CD8+ T cells and their trafficking in orchestrating the anti‐tumor response.